Publications by authors named "G Grimbizis"
Objective: The traditional histopathological analysis of endometrial cancer (EC) is the main risk group classification tool (low, intermediate, high-intermediate, and high) for the implementation of adjuvant treatment. The International Federation of Gynecology and Obstetrics staging system of EC has incorporated a new molecular classification that serves as a new triage tool for optimal treatment planning for these patients. Our study aimed to investigate the prognostic role of the new molecular classification in EC.
View Article and Find Full Text PDFPurpose: When oncological waiting lists are prolonged, gynecological oncology units are forced to delay operations, especially for endometrial cancer (EC) due to its good prognosis among gynecological cancers. The aim of this study is to evaluate the impact of delay in the oncological outcomes of these patients.
Methods: This is a retrospective analysis of all women with EC treated in our clinic, 2012-2019.
Article Synopsis
- The study aimed to evaluate the long-term outcomes, satisfaction, and reasons for disappointment in patients with advanced pelvic organ prolapse who underwent LeFort colpocleisis (LFC).
- Conducted between 2007 and 2021, the study included 141 patients and used surveys to assess their health and satisfaction 61.65 months after surgery.
- Results indicated a low rate of prolapse recurrence and no regrets about sexual function loss; however, persistent urinary incontinence correlated with decreased satisfaction and regret.
Introduction And Hypothesis: Various instruments are used to evaluate the severity of stress urinary incontinence (SUI) in clinical trials for SUI surgery. We conducted a scoping review with the primary aim of investigating the use of such instruments.
Methods: A comprehensive search in PubMed/MEDLINE, Cochrane Library, ClinicalTrials.
External Validation of the New 2023 International Federation of Gynecology and Obstetrics Staging System in Endometrial Cancer Patients: 12-Year Experience from an European Society of Gynecological Oncology-Accredited Center.
Medicina (Kaunas)
August 2024
Article Synopsis
- The new molecular classification of endometrial cancer is changing how doctors manage the disease, supported by a recently updated FIGO staging system that includes molecular substages for early-stage cases.
- A study analyzed patient records from a hospital from 2012 to 2023, focusing on stage shifts and treatment outcomes, revealing that 15.5% of patients experienced a shift in their cancer stage, mainly from earlier stages to stage IIC.
- The 2023 FIGO staging system shows improved differentiation of early-stage endometrial cancer prognoses while demonstrating similar prognostic accuracy as the previous 2009 system.